Kamada Pharmaceuticals - Company Profile
Powered by 
All the data and insights you need on Kamada Pharmaceuticals in one report.
$295
- Save hours of research time and resources with
our up-to-date Kamada Pharmaceuticals Strategy Report
- Understand Kamada Pharmaceuticals position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Kamada Pharmaceuticals (Kamada) develops and markets plasma-derived protein therapeutics for the treatment of lung diseases, asthma, Japanese encephalitis, hemophilia, and orphan diseases. It also distributes plasma-derived protein therapeutics to other pharmaceutical companies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
R&D efforts are focused on four product categories- immunoglobulins, respiratory, critical care, and other products. Major pipeline products include inhaled AAT in phase III clinical trials for AAT deficiency; recombinant AAT in the early development phase for AAT deficiency; and AAT (liquid) in ex-vivo study phase for organ preservation. Kamada employs its proprietary platform technology and harnesses its capabilities in extraction and purification of human plasma to produce various plasma-derived proteins, and AAT in high-purity, liquid form. In FY2022, the company spent US$13.2 million on its R&D activities, which as a percentage of revenue stood at 10.2%, and grew 15.8% YoY. As of December 31, 2022, the company owns 11 families of patents in the US, the European Union, Russia, Turkey, Israel, certain Latin American countries, Canada, Australia, and other countries. It also has one PCT patent application.
Business Segments
Overview
-Offers products to complement the proprietary products segment. -Distributes respiratory products for chronic pulmonary infection due to pseudomonas aeruginosa in patients six years and older with cystic fibrosis and Foster for treatment of asthma using a combination product. -Distributes immunoglobins including IVIG 5% for immunodeficiency-related conditions, Varitect for preventive treatment after exposure to the virus that causes chickenpox and zoster herpes, Zutectra for hepatitis B virus (HBV) re-infection in HBV-DNA negative patients six months after liver transplantation for hepatitis B induced liver failure, Hepatect CP to Prevent contraction of Hepatitis B by adults and children older than two years, Ruconest for treatment of acute angioedema attacks with hereditary angioedema (HAE) in adults due to C1 esterase inhibitor deficiency and Megalotect that contains antibodies to neutralize cytomegalovirus viruses and prevent their spread in immunologically impaired patients. -Distributes critical care products including heparin sodium injection for the treatment of thrombo-embolic disorders such as deep vein thrombosis, acute arterial embolism or thrombosis, thrombophlebitis, pulmonary embolism, fat embolism, prophylaxis of deep vein thrombosis and thromboembolic events and Albumin and Albumin 4% to maintains a proper level in the patient’s blood plasma. -Distributes coagulation factors including Factor VIII for the treatment of hemophilia type A diseases, and factor IX for the treatment of hemophilia type B disease. -Also offers a vaccine for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
-Offers plasma-derived protein therapeutics derived from human serum. -Focuses on four product categories- immunoglobulins, respiratory, critical care, and other products. -Manufactures anti-snake venom products from equine-based serum. -Offers respiratory products based on synthetic raw materials or raw materials derived from animal sources. -Offers immunoglobulins for passive post-exposure prophylaxis against rabies infection; for prophylaxis of hemolytic disease of newborns; for treatment of immune thermobocytopunic purpura; and Snake bite antiserum for treatment of snake bites. -Other products include Human transferring which is indicated not for human use.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer